Cocrystal Pharma, Inc.

Cocrystal Pharma is a biotechnology company focused on developing antiviral therapeutics for serious and chronic viral diseases. The company employs structure-based drug discovery technologies to create treatments targeting influenza viruses, coronaviruses (including SARS-CoV-2 and MERS-CoV), norovirus, respiratory virus infections, and hepatitis C virus. Its pipeline includes CC-42344, a PB2 inhibitor in Phase 2a clinical trials for pandemic and seasonal influenza A, with an inhaled formulation being evaluated for prophylactic use; CDI-988, an oral pan-viral compound in Phase 1 trials for norovirus and coronavirus infections; and CC-31244, an HCV non-nucleoside inhibitor that completed Phase 2a trials.

The company has established research and licensing partnerships to support its development efforts. Cocrystal maintains a license and research collaboration agreement with Merck Sharp & Dohme Corp. for influenza A/B antiviral discovery and development, and a separate license agreement with Kansas State University Research Foundation for antiviral compounds targeting norovirus and coronavirus infections.

Based in Bothell, Washington, Cocrystal Pharma operates as a small-scale biotechnology firm with 11 full-time employees. The company was founded in 2006 and is listed on the Nasdaq exchange.